Shield Therapeutics plc

this announcement contains inside information for the purposes of Article 7 of Regulation 596/2014. Shield Therapeutics plc (" Shield " or the "Group") Shield reports top-line results from pivotal Phase III study of Feraccru (Ferric Maltol) in the treatment of IDA in patients with CKD - Primary efficacy endpoint not achieved - Tolerability profile of Feraccru reconfirmed - A review of the full dataset will be conducted to better understand the result - Feraccru remains commercially available for IBD patients with IDA through Shield and its commercial partners in Europe and other ongoing clinical studies will continue London, UK, 5 February 2018: Shield Therapeutics plc (LSE.)

This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014. Shield Therapeutics plc ("Shield" or the "Group")

Loading..

Tags:

  This, Announcement, Inside, Contains, This announcement contains inside

Information

Related search queries